Dhruv Bhutani has been writing about consumer technology since 2008, offering deep insights into the Android smartphone landscape through features and opinion pieces. He joined Android Police in 2023, ...

Grow Therapy, a hybrid mental health provider, is introducing AI-powered journaling to help patients reflect between therapy sessions. The announcement marks the first time the company is offering ...

It might be on your bookshelf, in a junk drawer or collecting dust under a pile of papers you flung onto your desk, but there’s a good chance you have a journal. A collection of untouched blank pages ...

Brensocatib (Brinsupri; Insmed) gains FDA approval as the first treatment for bronchiectasis, offering hope to patients with the chronic lung disease. The FDA has approved brensocatib (Brinsupri; ...

Tumor infiltrating lymphocyte (TILs) therapy or tumor-derived autologous T cell immunotherapy is a form of immunotherapy that uses your body’s own immune cells to target and destroy cancer. It ...

Investors have struck a deal to buy a majority stake in HistoSonics, valuing the company whose noninvasive therapy for liver tumors shows promise in other diseases at $2.25 billion. An investor group ...

Surgical procedure. Image by Pfree2014 - Own work, CC BY-SA 4.0 Surgical procedure. Image by Pfree2014 - Own work, CC BY-SA 4.0 “Dancing molecules”, as dubbed by the researchers, is a promising new ...

EARLY treatment with intravenous immunoglobulins (IVIG) significantly improves long-term outcomes and survival in patients with anti-IgLON5 disease, according to findings from a large international ...

Mantle Cell Lymphoma: Optimal Treatment With Bruton Tyrosine Kinase–Targeted Approaches ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for ...

Writer Suleika Jaouad has been keeping a journal for as long as she could hold a pen. It got her through her battle with leukemia at age 22, life after treatment and then the pandemic. But at a ...

Editor’s Note: As of July 22, 2025, Sarepta Therapeutics has temporarily paused shipments of Elevidys for all DMD patients in the US. According to the Company, “this proactive step will allow Sarepta ...